The Leadership Team
Steve Yang, Ph.D.
Co-CEO, Head of RSD, Head of WuXi Testing
Formerly Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, previous roles including Vice President and Head of research and development (R&D) Asia at Pfizer. Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco.
Francis L. Tse, Ph.D.
Vice President & Chief Scientific Officer
Dr. Francis L. Tse has a wealth of experience in pharmaceutical development. Prior to joining WuXi AppTec, Dr. Tse served as Assistant Professor of Pharmacy at Rutgers University, then Vice President of Drug Metabolism & Bioanalytics at Novartis Pharma. Dr. Tse has published over 130 research articles and six books, including “Handbook of LC-MS Bioanalysis,” which has been translated into Chinese (Science Press, Beijing, 2017). Dr. Tse served on the Board of Directors of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQC), and is a Fellow of the American Association of Pharmaceutical Scientists (AAPS), Academy of Pharmaceutical Research and Science (APRS), and American College of Clinical Pharmacology (ACCP). In 2006, he received the prestigious Outstanding 50 Asian Americans in Business award. He received his B.S., M.S. and Ph.D. degrees from the University of Wisconsin-Madison.
Vice President of Operations
Hui Xu has over 20 years’ experience in operations and management for Good Laboratory Practice (GLP) facilities. As Vice President of Operations, she is fully responsible for the internal operations process and cross-function coordination with headquarters. Prior to joining WuXi AppTec in 2008, Hui worked in a Chinese government laboratory for 17 years. Hui has extensive experience in toxicology and drug safety evaluations in China. Under her leadership, the team successfully passed a series of regulatory audits including U.S. Food and Drug Administration (FDA), Organization for Economic Co-operation and Development (OECD) and National Medical Products Administration (NMPA) GLP inspections, AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) inspections, internal Quality Assurance (QA) audits and sponsor animal welfare audits. Hui actively participated in the development of the NMPA toxicology guidelines and the most recent revision of the NMPA GLP regulatory policy.
Vice President & Head of Toxicology
Bill Harrison has over 30 years’ experience in the contract research organization industry with a strong record of growth. Prior to joining WuXi AppTec, he was founder and CEO of VIDA Sciences, a company serving contract research organizations focusing on performance improvement. Earlier, Bill was President and COO of MPI Research, one of the largest preclinical providers in the world, where he led the company through a substantial growth period. Prior to MPI, Bill was Director of Regulatory Affairs and Operations at Pharmaco-LSR, now a part of Envigo. Bill is a former President of the US Society of Quality Assurance (SQA) and currently serves on the Board for the American Life Sciences Innovation Council. He earned a B.S. degree in biomedical engineering from the New Jersey Institute of Technology and has been an invited lecturer in North America, Japan, China and Australia.
Vice President of International Sales & Marketing
Ed Amat has over 27 years of successful performance in senior sales leadership, sales, marketing, public relations and client services in the pharmaceutical industry. Previously, Ed worked for MPI Research as Senior Director of Sales for North America and Europe, leading to Vice President of Global Sales and Marketing. At MPI, Ed led the commercial team, which sustained top-line YoY sales increase above company and industry rates. During his seven years at MPI, he also served on the executive leadership team supporting corporate decision making, direction and P&L management. Prior to MPI, Ed held pharmaceutical commercial functions at Pfizer and legacy companies, having been recognized with multiple sales and leadership awards. Ed is a former principal owner of a diagnostic medical testing company and recently served as a commercial officer with a drug manufacturing software company.
Jing Shi, Ph.D.
Vice President and Global Head of Bioanalytical Services
Dr. Jing Shi joined WuXi AppTec in 2014, as Vice President and global Head of Bioanalytical Services in the Laboratory Testing Division. She has extensive experience across various stages of drug development – including preclinical/clinical bioanalytical analysis, toxicology, cell line development, process development, biologics drug substance/drug product characterization, and more. Dr. Shi brings this wide-ranging experience to her work leading WuXi AppTec’s Immunochemistry Bioanalytical department, and managing multisite operations. Together with her team, Dr. Shi provides bioanalytical method development, validation, and sample testing services following Good Laboratory Practice (GLP)/Good Clinical Practice (GCP) guidelines. Before joining WuXi AppTec, Dr. Shi held leadership positions with AstraZeneca and Sigma in the U.S. In her most recent role at Sigma, Dr. Shi headed the immunoassay laboratory, where she was responsible for Good Manufacturing Practice (GMP) lot release/stability testing and GLP bioanalytical testing using immunochemistry and cell-based platforms. Dr. Shi received her B.S. in Cell Biology and Genetics from Peking University, and her Ph.D. in Cell Biology from the University of Virginia.
Liang Shen, Ph.D.
Vice President & Head of DMPK
Dr. Liang Shen has over 17 years’ experience in Drug Metabolism & Pharmacokinetics, Toxicology, Clinical Pharmacology, and Therapeutic Drug Monitoring. Dr. Shen has published or co-authored over 50 research articles, led or participated in the translation of 3 books including “ADME-Enabling Technologies in Drug Design and Development” into Chinese (Science Press, Beijing, 2020). His rich experience in drug discovery, Pre-Clinical Candidate (PCC) profiling and Investigational New Drug (IND) submission has successfully supported multiple pipelines in the fields of Oncology, Immuno-Oncology, Immunology, Metabolic diseases, Infectious diseases, Central Nervous System (CNS) & Cardiovascular diseases to proof-of-concept at clinical stage. He received his Ph.D. degree from the University of Georgia.